

**CONCISE COMMUNICATION**

DOI 10.1002/art.40767

**Time to include fine specificity anti-citrullinated protein antibodies in the routine diagnosis and management of rheumatoid arthritis?**

Antibodies to citrullinated protein antigens (ACPAs) are part of the classification criteria for rheumatoid arthritis (RA) (1). ACPAs can be measured using generic tests, such as the cyclic citrullinated peptide (CCP) assays, that use artificially generated synthetic peptides with no homology to known proteins, which provide good diagnostic sensitivity and specificity. Peptides from real autoantigens (fine specificities) tend to be of lower diagnostic sensitivity and are used primarily for research into disease pathogenesis, rather than clinical management. In a recent study (2), we found 2 groups of ACPA fine specificities associated with different RA risk factors. One, dominated by antibodies to citrullinated  $\alpha$ -enolase peptide 1 (CEP-1), was linked to smoking and shared epitope as previously described (3). The second group, linked to antibodies to a citrullinated peptide from tenascin-C (cTNC5), was associated with infection with the periodontal pathogen *Prevotella intermedia*. The relative distinctions between anti-CEP-1 and anti-cTNC5 prompted us to ask whether testing for these 2 fine specificities in combination with anti-CCP2 would be clinically useful in improving diagnosis or identifying clinical subsets among patients with RA.


We reanalyzed previous data from 287 patients with RA and 330 osteoarthritis controls, and we retested all of the sera for anti-CEP-1 using a commercially available anti-CEP-1 enzyme-linked immunosorbent assay (Euroimmun), optimized for clinical use. The diagnostic sensitivity with anti-CEP-1 was increased from 39% (2) to 48%, with a specificity of 98%. We then examined whether the addition of anti-CEP-1 and anti-cTNC5 to CCP2 increased the overall diagnostic sensitivity. We identified 8 patients with RA who were negative for anti-CCP2 but positive for either or both of the fine specificities (Figure 1A), increasing the overall diagnostic sensitivity with ACPA from 84.5% obtained with anti-CCP2 alone to 87% if all 3 assays were combined. We predict that this modest increase in sensitivity could be an underestimate caused by ascertainment bias because anti-CCP2 positivity may have influenced the recruitment of patients to this cohort. In previous studies, using cohorts in which many of the patients were recruited before the CCP tests became available, anti-CEP-1 and/or anti-cTNC5 positivity was higher in the anti-CCP2-negative RA patients, increasing overall diagnostic sensitivity by ~5% (2–4). Therefore, the inclusion of these 2 additional fine specificities at the point of diagnosis could increase the sen-

sitivity even further, though clearly this needs to be confirmed in prospective studies.

We then investigated whether positivity for anti-CEP-1 and/or anti-cTNC5 identified distinct clinical subsets. For this analysis, we omitted the anti-CCP2-negative patients, as numbers were too small for statistical evaluation. We identified no difference in joint disease between patients who were anti-cTNC5 positive versus those who were anti-CEP-1 positive. However, when both fine specificities were combined with anti-CCP2, the 28-joint Disease Activity Score (DAS28) (5) in patients positive for all 3 markers was significantly increased ( $P = 0.038$ ) compared to that in patients positive for only CCP2, with the difference in the Health Assessment Questionnaire score (6) approaching significance ( $P = 0.073$ ). Triple-positive patients also had significantly higher levels of anti-CCP2 ( $P < 0.001$ ) and rheumatoid factor ( $P < 0.001$ ) (Figure 1B). This increase in disease severity with multiple antibody specificities is perhaps not surprising, as a similar phenomenon has long been known to occur in systemic lupus erythematosus (SLE) (7).

In SLE, at least 6 different specificities would be routinely examined in every patient at presentation, with diagnosis established in the small proportion of antinuclear antibody-negative patients by the presence of anti-Ro antibodies. The same antibody also identifies rare but important clinical subsets: for example, an association with congenital heart block in babies of anti-Ro-positive mothers (7). In our patients with RA, no distinct clinical subsets were found, but we only examined joint-specific variables. It is possible that associations with extraarticular features may be recognized in future studies. Indeed, while anti-citrullinated vimentin antibodies are linked with bone loss (8), anti-citrullinated fibrinogen antibodies have been associated with atherosclerosis (9). For anti-CEP-1, a link with rheumatoid lung disease may be predicted by the association with smoking (3) and a high rate of positivity in patients with RA and bronchiectasis (10). Whether different ACPA fine specificities actively drive distinct aspects of joint disease and/or comorbidities also remains to be fully understood. We suggest that the only way to establish whether fine specificities are useful in improving diagnosis or identifying clinical subsets is to incorporate at least these 2 fine specificities into prospective studies so that in RA, multiple antibody assays become routine parts of clinical diagnosis and management.

Supported by the European Community IMI (Innovative Medicines Initiative) project BTCure (grant 115142-2), the Kennedy Trust for Rheumatology Research (grant AZRYXS00), and a Veterans Affairs Clinical Science Research and Development Merit Award (CX000896). Dr. Mikuls' work was supported by a grant from the NIH/National Institute of General Medical Sciences (U54-GM-115458). Dr. Midwood's work was supported by an Arthritis Research UK Senior Fellowship (grant 20003). Drs. Schwenzer, Venables, and Midwood



**Figure 1.** **A**, Venn diagram showing the overlap between citrullinated  $\alpha$ -enolase peptide 1 (CEP-1), citrullinated tenascin-C (cTNC5), and cyclic citrullinated peptide 2 (CCP2) antibody responses in 287 rheumatoid arthritis (RA) patients. For each anti-citrullinated protein antibody (ACPA), the total number of patients with positivity is shown in parentheses; overlaps in positivity are represented by numbers within the circles. Thirty-six patients (12.5%) were negative for CEP-1, cTNC5, and CCP2 antibodies (including 3 patients for whom no data on anti-CCP2 were available). **B**, Disease characteristics of patients with RA according to positivity for different combinations of ACPA. # = by analysis of variance (ANOVA); ## = by Kruskal-Wallis test; ### = by chi-square test; a = ANOVA with post hoc pairwise comparisons; b = by Kruskal-Wallis test with Dunn's test for pairwise comparisons. DAS28-CRP = 28-joint Disease Activity Score using the C-reactive protein level; HAQ = Health Assessment Questionnaire; RF = rheumatoid factor.

have filed patents related to the diagnostic utility of cTNC5. Dr. Midwood is founder of, and consultant to, Nascient Ltd. Drs. Schwenzer and Quirke contributed equally to this work.

Anja Schwenzer, PhD  
Anne-Marie Quirke, PhD  
Anna B. Montgomery, DPhil  
Patrick J. Venables, MD, FRCP  
*Kennedy Institute of Rheumatology  
Oxford, UK*  
Harlan R. Sayles, MS  
*University of Nebraska Medical Center  
Omaha, NE*  
Wolfgang Schlumberger, PhD  
*Euroimmun Medizinische Labordiagnostika AG  
Lübeck, Germany*  
Jeffrey B. Payne, DDS, MDentSc  
*University of Nebraska Medical Center  
Lincoln, NE*  
Ted R. Mikuls, MD, MSPH  
*University of Nebraska Medical Center  
and Veterans Affairs Nebraska-Western  
Iowa Health Care System  
Omaha, NE*  
Kim S. Midwood, PhD   
*Kennedy Institute of Rheumatology  
Oxford, UK*

AUTHOR CONTRIBUTIONS

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Midwood had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Study conception and design.** Schwenzer, Quirke, Venables, Schlumberger, Payne, Mikuls, Midwood.  
**Acquisition of data.** Schwenzer, Quirke, Montgomery, Venables, Payne, Mikuls, Midwood.  
**Analysis and interpretation of data.** Schwenzer, Quirke, Venables, Sayles, Payne, Mikuls, Midwood.

1. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum* 2010;62:2569–81.

2. Schwenzer A, Quirke AM, Marzeda AM, Wong A, Montgomery AB, Sayles HR, et al. Association of distinct fine specificities of anti-citrullinated peptide antibodies with elevated immune responses to *Prevotella intermedia* in a subgroup of patients with rheumatoid arthritis and periodontitis. *Arthritis Rheumatol* 2017;69:2303–13.

3. Mahdi H, Fisher BA, Källberg H, Plant D, Malmström V, Rönnelid J, et al. Specific interaction between genotype, smoking and autoimmunity to citrullinated  $\alpha$ -enolase in the etiology of rheumatoid arthritis. *Nat Genet* 2009;41:1319–24.

4. Lundberg K, Kinloch A, Fisher BA, Wegner N, Wait R, Charles P, et al. Antibodies to citrullinated  $\alpha$ -enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. *Arthritis Rheum* 2008;58:3009–19.

5. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum* 1995;38:44–8.


6. Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. *Arthritis Rheum* 1980;23:137–45.

7. Venables PJ. Diagnosis and treatment of systemic lupus erythematosus. *BMJ* 1993;307:663–6.

8. Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. *J Clin Invest* 2012;122:1791–802.
9. Sokolove J, Brennan MJ, Sharpe O, Lahey LJ, Kao AH, Krishnan E, et al. Citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis. *Arthritis Rheum* 2013;65:1719–24.
10. Quirke AM, Perry E, Cartwright A, Kelly C, De Soyza A, Eggleton P, et al. Bronchiectasis is a model for chronic bacterial infection inducing autoimmunity in rheumatoid arthritis. *Arthritis Rheumatol* 2015;67:2335–42.

DOI 10.1002/art.40779

### Clinical Images: Lichen planus pigmentosus and frontal fibrosing alopecia mimicking discoid lupus erythematosus



The patient, a 77-year-old woman, presented with a 10-year history of discoid, scaly, pigmented, telangiectatic, and atrophic patches on the upper cheeks of the face (**A**) and gradually progressive alopecia of the frontal scalp (**B**). A cheek biopsy demonstrated interface dermatitis, epidermal hyperkeratosis and atrophy, dyskeratotic keratinocytes, and a superficial perivascular lymphohistiocytic infiltrate with pigment incontinence. In addition to the facial lesions, there was perifollicular erythema, scaling, and loss of follicular ostia along the frontal hairline, and alopecia of the lateral eyebrows (**B**). She had low-titer antinuclear antibodies (1:80 in a nucleolar pattern) and was negative for SSA and SSB antigens. Blood counts and findings of serum chemistry tests were unremarkable. A review of systems did not reveal additional abnormal findings. Prior to referral, discoid lupus erythematosus (DLE) had initially been diagnosed, and topical steroid treatment had been started. Although malar predilection, dyspigmentation/atrophy, and histopathology of the facial eruption could represent DLE, the reticular pattern and absence of follicular plugging were more consistent with lichen planus pigmentosus (LPP), and the alopecia of the frontal hairline and eyebrows best supports a concomitant diagnosis of frontal fibrosing alopecia (FFA). The combination of LPP and FFA has previously been described (1). LPP and FFA are considered to be within the spectrum of lichen planus (2). Erythema, telangiectasias, dyspigmentation, and atrophy are not uncommon in LPP and are features present in DLE. Histopathologic features of LPP may be similar to those of DLE. Distinguishing LPP and DLE is important as DLE may progress toward systemic disease and require systemic therapy. LPP/FFA usually occurs in the absence of systemic disease, and treatment is skin-directed. Moreover, the etiology of hair loss in an autoimmune patient has implications for the classification of systemic lupus erythematosus. LPP and DLE can both present as alopecia. Therefore, diagnostic accuracy entails a thorough clinicopathologic confirmation and/or consultation with a dermatologist.

*Supported by the Veterans Health Administration.*

1. Dlova NC. Frontal fibrosing alopecia and lichen planus pigmentosus: is there a link? *Br J Dermatol* 2013;168:439–42.
2. Gorouhi F, Davari P, Fazel N. Cutaneous and mucosal lichen planus: a comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis. *Sci World J* 2014;2014:742826.

Carolyn J. Kushner, BA  
 Josef Symon S. Concha, MD  
 Corporal Michael J. Crescenzo VAMC  
 and University of Pennsylvania  
 David R. Pearson, MD  
 Corporal Michael J. Crescenzo VAMC  
 and University of Pennsylvania  
 and University of Minnesota  
 Minneapolis, MN  
 Victoria P. Werth, MD  
 Corporal Michael J. Crescenzo VAMC  
 and University of Pennsylvania  
 Philadelphia, PA